Evidence map›Paper›PMID 25768046›Full record

ArticleACS nano2015

Phage-display-guided nanocarrier targeting to atheroprone vasculature.

Lucas H Hofmeister, Sue Hyun Lee, Allison E Norlander, Kim Ramil C Montaniel, Wei Chen, David G Harrison, Hak-Joon Sung

Abstract read
In one paragraph

Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Roles of eNOS in atherosclerosis treatment.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Oxidative Stress and Hypertensive Diseases.The Medical clinics of North America · 2017
    Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lucas H Hofmeister†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Sue Hyun Lee†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Allison E Norlander†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Kim Ramil C Montaniel†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Wei Chen†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
David G Harrison†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Hak-Joon Sung†Department of Biomedical Engineering, ‡Division of Clinical Pharmacology, §Center for Vascular Biology, and ∥Division of Cardiovascular Medicine, Vanderbilt University, Nashville, Tennessee 37235, United States.
Vanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI MCGUINNESS, OWEN P · 1986 to 2011
$28.1M
Vascular specific ACE expression and atherosclerosisP01HL058000 · NHLBI · VANDERBILT UNIVERSITY · PI DIKALOV, SERGEY · 1998 to 2013
$20.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
THREE-TIERED PREVENTION MODEL TO BETTER SERVE ALL STUDENP30HD015052 · NICHD · VANDERBILT UNIVERSITY · PI DYKENS, ELISABETH MAY · 1985 to 2014
$18.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Therapeutic Modulation of Endothelial Cell TetrahydrobiopterinP01GM015431 · NIGMS · VANDERBILT UNIVERSITY · PI ROBERTS, JACKSON L · 2011 to 2015
$9.5M
Vanderbilt Mouse Metabolic Phenotyping CenterU2CDK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2016 to 2021
$6.3M
REGULATION OF VASCULAR FUNCTION BY THE ENDOTHELIUMR01HL039006 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRISON, DAVID G · 1987 to 2017
$5.5M
Neurovascular Unit on a Chip: Regional Chemical Communication, Drug and Toxin ResponsesUH3TR000491 · NCATS · VANDERBILT UNIVERSITY · PI GHOSH, CHAITALI, JANIGRO, DAMIR · 2014 to 2016
$3.8M
NCATS NIH HHS UH2 TR000491NCATS NIH HHS UH3 TR000491NCI NIH HHS CA68485NCI NIH HHS P30 CA068485NEI NIH HHS EY008126NHLBI NIH HHS F31 HL127986NHLBI NIH HHS P01 HL058000NHLBI NIH HHS P01HL058000NHLBI NIH HHS R01 HL039006NHLBI NIH HHS R01HL039006NHLBI NIH HHS R01 HL105294NHLBI NIH HHS R01HL105294NHLBI NIH HHS R01 HL108701NHLBI NIH HHS R01HL108701NHLBI NIH HHS R01 HL125865NICHD NIH HHS HD15052NICHD NIH HHS P30 HD015052NIDDK NIH HHS DK20593NIDDK NIH HHS DK58404NIDDK NIH HHS DK59637NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS P01 GM015431NIGMS NIH HHS P01GM015431
6 · The paper itself

Abstract

In regions of the circulation where vessels are straight and unbranched, blood flow is laminar and unidirectional. In contrast, at sites of curvature, branch points, and regions distal to stenoses, blood flow becomes disturbed. Atherosclerosis preferentially develops in these regions of disturbed blood flow. Current therapies for atherosclerosis are systemic and may not sufficiently target these atheroprone regions. In this study, we sought to leverage the alterations on the luminal surface of endothelial cells caused by this atheroprone flow for nanocarrier targeting. In vivo phage display was used to discover unique peptides that selectively bind to atheroprone regions in the mouse partial carotid artery ligation model. The peptide GSPREYTSYMPH (PREY) was found to bind 4.5-fold more avidly to the region of disturbed flow and was used to form targeted liposomes. When administered intravenously, PREY-targeted liposomes preferentially accumulated in endothelial cells in the partially occluded carotid artery and other areas of disturbed flow. Proteomic analysis and immunoblotting indicated that fibronectin and Filamin-A were preferentially bound by PREY nanocarriers in vessels with disturbed flow. In additional experiments, PREY nanocarriers were used therapeutically to deliver the nitric oxide synthase cofactor tetrahydrobiopterin (BH4), which we have previously shown to be deficient in regions of disturbed flow. This intervention increased vascular BH4 and reduced vascular superoxide in the partially ligated artery in wild-type mice and reduced plaque burden in the partially ligated left carotid artery of fat fed atheroprone mice (ApoE(-/-)). Targeting atheroprone sites of the circulation with functionalized nanocarriers provides a promising approach for prevention of early atherosclerotic lesion formation.

Indexed as

NanostructuresPeptide LibraryAmino Acid SequenceAnimalsApolipoproteins EAtherosclerosisBiopterinsCarotid ArteriesDisease SusceptibilityDrug CarriersMaleMiceMolecular Sequence DataNanomedicineOligopeptidesApolipoproteins EBiopterinsDrug CarriersOligopeptidesPeptide Librarysapropterindisturbed flow atherosclerosisliposomephage displaytetrahydrobiopterin

Identifiers

PMID25768046
PMCPMC4654777
OpenAlexW2025395254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.